Clinic Roundup
Dendreon Corp., of Bridgewater, N.J., reported findings from several ongoing or completed studies of Provenge (sipuleucel-T) in advanced prostate cancer ahead of the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium in Orlando, Fla.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.